Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel T Robinson

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Bone Research|March 28, 2018
Mechanically induced Ca<sup>2+</sup> oscillations in osteocytes release extracellular vesicles and enhance bone formationAndrea E Morrell, Genevieve N Brown, Samuel T Robinson, et al.
The Journal of Infectious Diseases|December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell LinesGregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
PLOS Global Public Health|September 11, 2025
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort studyNonhlanhla N Mkhize, Shuying Sue Li, Jiani Hu, et al.
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
JAMA Network Open|May 23, 2024
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized TrialsLeigh H Fisher, Jia Jin Kee, Albert Liu, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Bone Research|March 28, 2018
Mechanically induced Ca<sup>2+</sup> oscillations in osteocytes release extracellular vesicles and enhance bone formationAndrea E Morrell, Genevieve N Brown, Samuel T Robinson, et al.
The Journal of Infectious Diseases|December 13, 2024
HVTN 123: A Phase 1, Randomized Trial Comparing Safety and Immunogenicity of CH505TF gp120 Produced by Stably and Transiently Transfected Cell LinesGregory J Wilson, L W Preston Church, Colleen F Kelley, et al.
PLOS Global Public Health|September 11, 2025
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort studyNonhlanhla N Mkhize, Shuying Sue Li, Jiani Hu, et al.
NPJ Vaccines|January 17, 2026
Association between COVID-19 vaccine efficacy and epidemic force of infectionJing Xu, M Elizabeth Halloran, Mia Moore, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 25, 2024
Safety and Immunogenicity of a DNA Vaccine With Subtype C gp120 Protein Adjuvanted With MF59 or AS01B: A Phase 1/2a HIV-1 Vaccine TrialNigel Garrett, One Dintwe, Cynthia L Monaco, et al.
The Lancet. HIV|May 1, 2024
Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trialIan Frank, Shuying S Li, Nicole Grunenberg, et al.
Vaccine|February 23, 2026
Impact of prior SARS-CoV-2 acquisition on binding and neutralizing antibody responses following COVID-19 vaccination: A cross-protocol analysis of individual-level data from six phase 3 clinical trialsAaron Hudson, Scott Borgetti, Anne-Marie Rick, et al.
JAMA Network Open|July 13, 2023
Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical TrialsDeborah A Theodore, Angela R Branche, Lily Zhang, et al.
JAMA Network Open|May 23, 2024
SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals: A Secondary Cross-Protocol Analysis of 4 Randomized TrialsLeigh H Fisher, Jia Jin Kee, Albert Liu, et al.
Ebiomedicine|June 14, 2025
Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling studyYunda Huang, Lily Zhang, Huub Gelderblom, et al.
Pageof 3